Edition:
United Kingdom

People: Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

233.62USD
15 Jul 2019
Change (% chg)

-- (--)
Prev Close
$233.62
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
840,582
52-wk High
$388.67
52-wk Low
$216.13

Sandrock, Alfred 

Dr. Alfred W. Sandrock, Jr. M.D. Ph.D. has served as an Executive Vice President and Chief Medical Officer of Biogen Inc. since October 2017. Prior to that, from April 2016 to December 2016, Mr. Vounatsos served as our Executive Vice President and Chief Commercial Officer. Prior to joining Biogen, Mr. Vounatsos spent 20 years at Merck & Co., Inc. (Merck), a pharmaceutical company, where he most recently served as President, Primary Care, Customer Business Line. In this role, he led Merck’s global primary care business unit, a role which encompassed Merck’s cardiology-metabolic, general medicine, women’s health and biosimilars groups and developed and instituted a strategic framework for enhancing the company’s relationships with key constituents, including the most significant providers, payors and retailers and the world’s largest governments. Mr. Vounatsos previously held leadership positions across Europe and in China for Merck. Prior to that, Mr. Vounatsos held management positions at Ciba-Geigy, a pharmaceutical company.

Basic Compensation

Total Annual Compensation, USD 1,160,130
Restricted Stock Award, USD 6,820,260
Long-Term Incentive Plans, USD --
All Other, USD 188,997
Fiscal Year Total, USD 8,169,380

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

Stelios Papadopoulos

613,476

Michel Vounatsos

16,168,600

Jeffrey Capello

4,476,720

Ginger Gregory

--

Susan Alexander

6,353,780

Michael Ehlers

7,046,650
As Of  31 Dec 2018